BioCentury
ARTICLE | Clinical News

AZD4547: Phase II data

June 1, 2015 7:00 AM UTC

An open-label, U.K. Phase II trial in patients with fibroblast growth factor (FGF) receptor 1 ( FGFR1; CD331)- or FGFR2-amplified tumors showed that twice-daily 80 mg oral AZD4547 for the first 2 we...